StreetAlpha.app
Home › Stocks › AKTS

Aktis Oncology, Inc. (AKTS)

$16.31
▲ +0.93%
LAST CLOSE · NOV 17

Aktis Oncology develops radiopharmaceutical cancer treatments that deliver radioactive material directly to tumors. It last closed at $16.31 on Nov 17, up 0.93% on the day. The average 12-month price target from 2 analysts is $37.50 (+129.9% from the last close), with a high of $40.00 and a low of $35.00.

AI Auto Pilots
Is AKTS in one of our four AI portfolios? Sign in free to see

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated AKTS in the past 90 days, not enough for a consensus
Average 12-month target
$37.50
▲ 129.9% upside

Based on 2 analysts who set a price target on AKTS in the past 90 days. The average target is $37.50, with a high of $40.00 and a low of $35.00, compared with the last close of $16.31.

Low $35.00Avg $37.50High $40.00
Blue marker: last close $16.31
Highest target$40.00
Average target$37.50
Lowest target$35.00
Latest rating changes
WedbushReiterated
Oct 2Buy$35
OppenheimerInitiated
Sep 9Buy$40
WedbushInitiated
Aug 19Buy$35
BMO CapitalInitiated
Aug 19Buy$37
JP MorganMaintained
Jul 14Buy$33
DateFirmActionRatingPrice target
Oct 2WedbushReiteratedBuy$35
Sep 9OppenheimerInitiatedBuy$40
Aug 19WedbushInitiatedBuy$35
Aug 19BMO CapitalInitiatedBuy$37
Jul 14JP MorganMaintainedBuy$33
Loading…

Technical Analysis

AKTS · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 27% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $16.12, and the nearest resistance the Pivot R1 at $16.65.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.3%/day
Key levels
$34.1952 week high+109.6%
$21.83100 day average+33.8%
$20.73200 day average+27.1%
$18.1550 day average+11.3%
$16.78Swing high (Oct 22)+2.9%
$16.65Pivot R1+2.1%
$16.31Last close
$16.1220 day average−1.2%
$16.12Pivot−1.2%
$15.79Pivot S1−3.2%
$15.59Swing low (Oct 27)−4.4%
$14.0052 week low−14.2%
Indicators
RSI (14)46.71Middle of its rangeNeutral
MACD-0.43Above its signal lineBullish
Stochastic61.1Middle of its rangeNeutral
ADX (14)22.4Weak trend
Williams %R-40.3Oversold below −80, overbought above −20Neutral
CCI (20)2.5Oversold below −100, overbought above 100Neutral
Rate of change+9.2%Change over 10 sessionsBullish
ATR (14)$1.02Typical daily range, 6.3% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for AKTS

What happened before

See how AKTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in AKTS in the last 90 days.

Loading…

See today’s whale options flow across the market →

AKTS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲84 buying vs 41 selling
  • ▲Shares held by funds +7.7%
  • ▲Funds holding +11
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding125114+9.6%
In funds' top 10550.0%
Held by funds–––
New / increased30 / 5451 / 27+7.7%
Reduced / sold out23 / 1818 / 6+70.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AKTS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKTS is in one of them and how their past AKTS trades turned out.

AKTS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AKTS in an article yet. Here's the latest on the wider market.

About Aktis Oncology

Aktis Oncology is a company based in Boston that develops radiopharmaceuticals, which are cancer treatments that carry radioactive material directly to tumors. Its main focus is a platform built on small engineered proteins that bind to targets on cancer cells. Its lead candidate targets Nectin-4, a protein found on several solid tumor types, and is being tested in clinical trials for urothelial cancer and other tumors. The company works with isotope suppliers and contract manufacturers to supply these treatments to cancer patients and their doctors.

Headquarters
Boston, MA